FOXP3 Over-expression Inhibits Melanoma Tumorigenesis Via Effects on Proliferation and Apoptosis

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 Jan 11

PMID 24406338

Citations 28

Authors

BeeShin Tan

Matthew Anaka

Siddhartha Deb

Claudia Freyer

Lisa M Ebert

Anderly C Chueh

Sheren Al-Obaidi

Andreas Behren

Aparna Jayachandran

Jonathan Cebon

Weisan Chen

John M Mariadason

Affiliations

Soon will be listed here.

Abstract

The Forkhead box P3 (FOXP3) transcription factor is the key driver of regulatory T cell (Treg cells) differentiation and immunosuppressive function. In addition, FOXP3 has been reported to be expressed in many tumors, including melanoma. However, its role in tumorigenesis is conflicting, with both tumor suppressive and tumor promoting functions described. The aim of the current study was to characterize the expression and function of FOXP3 in melanoma. FOXP3 expression was detected by immunohistochemistry (IHC) in 12% (18/146) of stage III and IV melanomas. However expression was confined to fewer than 1% of cells in these tumors. Stable over-expression of FOXP3 in the SK-MEL-28 melanoma cell line reduced cell proliferation and clonogenicity in vitro, and reduced xenograft growth in vivo. FOXP3 over-expression also increased pigmentation and the rate of apoptosis of SK-MEL-28 cells. Based on its infrequent expression in human melanoma, and its growth inhibitory and pro-apoptotic effect in over-expressing melanoma cells, we conclude that FOXP3 is not likely to be a key tumor suppressor or promoter in melanoma.

Citing Articles

The Expression of Forkhead Box P3 T Regulatory Lymphocytes as a Prognostic Factor in Malignant Melanomas.

Gata V, Pasca A, Roman A, Muntean M, Morariu D, Bonci E Int J Mol Sci. 2024; 25(12).

PMID: 38928083 PMC: 11204253. DOI: 10.3390/ijms25126377.

Integrative functional genomic analyses identify genetic variants influencing skin pigmentation in Africans.

Feng Y, Xie N, Inoue F, Fan S, Saskin J, Zhang C Nat Genet. 2024; 56(2):258-272.

PMID: 38200130 PMC: 11005318. DOI: 10.1038/s41588-023-01626-1.

Identification of FOXP3 epithelial cells contributing to pancreatic proliferation and angiogenesis.

Gong R, Chen X, Sun X, Zhang Y, Wang J, Yu Q Am J Physiol Cell Physiol. 2023; 326(1):C294-C303.

PMID: 38047300 PMC: 11192472. DOI: 10.1152/ajpcell.00461.2023.

Genetic adaptation of skin pigmentation in highland Tibetans.

Yang Z, Bai C, Pu Y, Kong Q, Guo Y, Liu X Proc Natl Acad Sci U S A. 2022; 119(40):e2200421119.

PMID: 36161951 PMC: 9552612. DOI: 10.1073/pnas.2200421119.

Mechanism of activation and the rewired network: New drug design concepts.

Nussinov R, Zhang M, Maloney R, Tsai C, Yavuz B, Tuncbag N Med Res Rev. 2021; 42(2):770-799.

PMID: 34693559 PMC: 8837674. DOI: 10.1002/med.21863.

References

Wang L, Liu R, Li W, Chen C, Katoh H, Chen G . Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009; 16(4):336-46. PMC: 2758294. DOI: 10.1016/j.ccr.2009.08.016. View

Merlo A, Casalini P, Carcangiu M, Malventano C, Triulzi T, Menard S . FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009; 27(11):1746-52. DOI: 10.1200/JCO.2008.17.9036. View

Mann D . Targeted cancer therapeutics: the heartbreak of success. Nat Med. 2006; 12(8):881-2. DOI: 10.1038/nm0806-881. View

Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W . FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007; 129(7):1275-86. PMC: 1974845. DOI: 10.1016/j.cell.2007.04.034. View

Yamamoto M, Tsuji-Takayama K, Suzuki M, Harashima A, Sugimoto A, Motoda R . Comprehensive analysis of FOXP3 mRNA expression in leukemia and transformed cell lines. Leuk Res. 2007; 32(4):651-8. DOI: 10.1016/j.leukres.2007.08.020. View

Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F . Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2010; 125(1):65-72. DOI: 10.1007/s10549-010-0831-1. View

Cunha L, Morari E, Nonogaki S, Soares F, Vassallo J, Ward L . Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics (Sao Paulo). 2012; 67(5):483-8. PMC: 3351250. DOI: 10.6061/clinics/2012(05)13. View

Zhang H, Sun H . Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett. 2009; 287(1):91-7. DOI: 10.1016/j.canlet.2009.06.001. View

Ebert L, Tan B, Browning J, Svobodova S, Russell S, Kirkpatrick N . The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008; 68(8):3001-9. DOI: 10.1158/0008-5472.CAN-07-5664. View

10.

Droeser R, Obermann E, Wolf A, Wallner S, Wolf D, Tzankov A . Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells. Clin Breast Cancer. 2013; 13(4):264-70. DOI: 10.1016/j.clbc.2013.02.009. View

11.

Winerdal M, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A . FOXP3 and survival in urinary bladder cancer. BJU Int. 2011; 108(10):1672-8. DOI: 10.1111/j.1464-410X.2010.10020.x. View

12.

McInnes N, Sadlon T, Brown C, Pederson S, Beyer M, Schultze J . FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene. 2011; 31(8):1045-54. DOI: 10.1038/onc.2011.293. View

13.

Breitling R, Armengaud P, Amtmann A, Herzyk P . Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 2004; 573(1-3):83-92. DOI: 10.1016/j.febslet.2004.07.055. View

14.

Kim M, Chung N, Yoo N, Lee S . No mutation in the FOXP3 gene in acute leukemias. Leuk Res. 2010; 35(1):e10. DOI: 10.1016/j.leukres.2010.09.008. View

15.

Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan A, Stroud J . FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006; 126(2):375-87. DOI: 10.1016/j.cell.2006.05.042. View

16.

Hofmann O, Caballero O, Stevenson B, Chen Y, Cohen T, Chua R . Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008; 105(51):20422-7. PMC: 2603434. DOI: 10.1073/pnas.0810777105. View

17.

Jensen M, Jorgensen J, Binderup T, Kjaer A . Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008; 8:16. PMC: 2575188. DOI: 10.1186/1471-2342-8-16. View

18.

Takeda K, Takemoto C, Kobayashi I, Watanabe A, Nobukuni Y, Fisher D . Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Hum Mol Genet. 1999; 9(1):125-32. DOI: 10.1093/hmg/9.1.125. View

19.

Wu M, Hemesath T, Takemoto C, Horstmann M, WELLS A, Price E . c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 2000; 14(3):301-12. PMC: 316361. View

20.

Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y . Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 2011; 71(6):2162-71. PMC: 3070402. DOI: 10.1158/0008-5472.CAN-10-3268. View